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Abstract
Background: A substantial proportion of patients with acute myocardial infarction (AMI) did not receive invasive
therapy, defined as percutaneous coronary intervention and/or coronary artery bypass grafting. Aims of this study
were to evaluate predictors of non-invasive therapy in elderly compared to younger AMI patients and to assess the
association between invasive therapy and 28-day-case fatality.
Methods: From the German population-based registry, 3475 persons, consecutively hospitalized with an AMI
between 2009 and 2012 were included. Data were collected by standardized interviews and chart review. All-cause
mortality was assessed on a regular basis. Multivariable logistic regression analyses were conducted.
Results: The sample consisted of 1329 patients aged 28–65 years (age category [AC] 1), 1083 aged 65–74 years (AC 2),
and 1063 aged 75–84 years (AC 3). The proportion of patients receiving non-invasive therapy was 10.7, 17.7, and 35.8 %
in AC 1, 2, and 3, respectively. Predictors of non-invasive therapy in all ACs were non-ST segment elevation MI, bundle
branch block, reduced left ventricular ejection fraction, prior stroke, absence of hyperlipidemia, and low creatine kinase.
Elderly women (≥65 years) were less likely to receive invasive therapy. Stratifying the models by type of AMI revealed
fewer predictors in patients with ST segment elevation MI. Regarding 28-day-case fatality, strong inverse relations with
invasive therapy were seen in all AC: odds ratio of 0.35 (95 % confidence interval [CI] 0.15–0.84), 0.45 (95 % CI 0.22–0.92)
, and 0.39 (95 % CI 0.24–0.63) in AC 1, 2 and 3, respectively.
Conclusion: In today’s real-life patient care we found that predictors of non-invasive therapy were predominantly the
same in all age groups, but differed particularly by type of AMI. Further research is necessary to investigate the real
reasons for non-invasive therapy, especially among elderly women. Moreover, we confirmed that receiving invasive
therapy was inversely associated with 28-day-case fatality independent of age.
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Background
Percutaneous coronary intervention (PCI) and coronary
artery bypass grafting (CABG) are today’s standard inva-
sive treatment options for patients with acute coronary
syndrome (ACS) independent of patient’s chronological
age [1–5]. Over the last years, an increasing trend in use
of these invasive procedures in patients with an acute
myocardial infarction (AMI) was reported in several
registry studies [6–9]. Nevertheless, there is still a sub-
stantial proportion of AMI patients who neither receive
PCI nor CABG, even though being eligible for invasive
therapy. Earlier studies have determined reasons for the
underuse of reperfusion therapy in ST-segment elevation
myocardial infarction (STEMI) patients and found that
several factors such as older age, female sex, delayed
presentation, comorbidities, prior stroke, prior MI, con-
traindications to the use of fibrinolytic agents and/or
mechanical reperfusion (e.g., bleeding risk) are related
with no reperfusion therapy in the acute setting [7, 9–
13]. To our knowledge, previous studies have not inves-
tigated predictive factors of invasive treatment in pa-
tients with non-ST segment elevation myocardial
infarction (NSTEMI) and did not distinct between youn-
ger and elderly persons beneath consideration of short-
term survival. The aim of this study was firstly to evalu-
ate predictive factors for non-invasive treatment in eld-
erly and younger AMI patients including the type of
AMI (e.g., STEMI, NSTEMI). Secondly, to assess the as-
sociation between invasive compared to non-invasive
therapy and 28-day-case fatality by age group in real-life
patient care.
Methods
Study design and data source
The present study is based on data from the population-
based MI registry in Augsburg, Germany, which was
established in 1984 as part of the World Health
Organization MONICA Project (MONItoring Trends
and Determinants in CArdiovascular disease). After the
termination of MONICA in 1995, the MI registry be-
came part of the framework of KORA (Cooperative
Health Research in the Region of Augsburg). Since 1984,
coronary deaths and non-fatal (at least 24 h surviving)
AMI cases of the 25- to 74-year old inhabitants of the
city of Augsburg and 2 adjacent counties (about 600,000
inhabitants) have been continuously registered. About
80 % of all AMI cases of the study region are treated in
the region’s major hospital, Klinikum Augsburg, a ter-
tiary care center offering 24/7 interventional cardiovas-
cular procedures, as well as heart surgery facilities. From
2009 onwards, the registry was extended for the elderly
up to 84 years. The methods of case identification, diag-
nostic classification of events, and data quality control
have been described in detail elsewhere [14, 15]. Since
2001, diagnostic criteria according to the European Soci-
ety of Cardiology and American College of Cardiology
criteria were used for case identification, including as-
sessment of troponin levels especially for identification
of NSTEMI [16].
Data collection
Patients were interviewed during hospital stay by trained
nurses using a standardized questionnaire to collect
sociodemographic characteristics, cardiovascular risk
factors, medical history of previous MI, stroke and co-
morbidities, and information on the acute event. Further
information on type of AMI, treatment procedures and
complications during hospital stay, vital signs, medical
history, and medication use during hospitalization were
collected by review of medical chart. Information pro-
vided by the patient concerning the medical history had
to be confirmed by chart review. Information on renal
dysfunction was collected by review of medical chart.
Data collection of the MONICA/KORA MI registry has
been approved by the ethics committee of the Bavarian
Medical Association (Bayerische Landesärztekammer)
and all study participants gave written informed consent.
Study population
The present study included all consecutive patients aged
25–84 years, who were hospitalized with a non-fatal
AMI between January 1, 2009, and December, 31, 2012
and survived longer than 24 h. From 3669 persons, we
excluded 194 (5.3 %) individuals with missing informa-
tion on any of the relevant covariables. Thus, the final
study population covered 3475 cases (2397 males and
1078 females) with AMI. Excluded patients due to miss-
ing covariable information were older (median age 72 vs.
69 years, p <0.0001), had more frequently a NSTEMI
(67.5 vs. 53.3 %) or bundle branch block (BBB) (12.4 vs.
9.5 %, p <0.0001), were less likely to receive an invasive
therapy (52.1 vs. 79.5 %, p <0.0001) and coronary angi-
ography (61.9 vs. 89.2 %, p <0.0001), and showed a
higher rate of 28-day-case fatality (23.7 vs. 7.4 %, p
<0.0001) compared to patients included in the study
population.
Definitions and outcome
The following 3 age categories (AC) were analyzed: AC
1) patients aged 25–64 years, AC 2) patients aged 65–74
years, and AC 3) patients aged 75–84 years. Patients
were grouped regarding their in-hospital treatment strat-
egy: invasive therapy was defined as PCI with stent im-
plantation or balloon dilatation or/and CABG; non-
invasive (conservative) therapy included patients treated
with thrombolysis and/or receiving coronary angiog-
raphy but without a treatment procedure. The type of
AMI was defined as STEMI, NSTEMI, or BBB. The BBB
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group contains newly developed left BBB, right BBB, and
pre-known BBB. Because we do not exactly know
whether all patients with a BBB had a newly developed
left BBB, which is considered as STEMI equivalent, we
displayed the BBB group as separate category.
The outcome of this study was 28-day-case fatality
after AMI. Mortality was assessed by checking the vital
status of all registered persons of the MONICA/KORA
MI registry on a regular basis. Death certificates were
obtained from local health departments.
Data analysis
Categorical variables were expressed as absolute num-
bers and percentages (%), continuous variables as me-
dian with interquartile range (25th and 75th percentiles).
For descriptive purpose, the 3 ACs were compared using
Chi2-test or Fisher’s exact test for categorical variables
and the Kruskal-Wallis test (Wilcoxon Analysis) for con-
tinuous variables.
To identify predictors that determined the selection of
in-hospital treatment strategy (invasive or conservative
therapy), multivariable logistic regression analyses were
performed for each AC and further stratified by type of
AMI. Variables analyzed as potential predictive factors
were sex (male/female), smoking (current smoker/ex-
smoker/never-smoker/missing), living alone (yes/no/
missing), body mass index ≥30 kg/m2 (yes/no), prior MI,
prior stroke, medical history of diabetes, hyperlipidemia,
hypertension, angina pectoris, and chronic obstructive
pulmonary disease (yes/no), renal dysfunction reported
in medical chart (yes/no), pre-hospital time (symptom
onset to arrival) [min] (continuous), left ventricular ejec-
tion fraction (LVEF) (> 30 %/≤ 30 %/not assessed or
missing), type of AMI (STEMI/NSTEMI/BBB), and peak
serum creatine phosphokinase (CPK) level (U/l) during
hospitalization (continuous). As criterion for entry in the
models, the explanatory variables must meet the 0.05
significance level in at least 1 AC in the bivariate analysis
with the in-hospital treatment strategy. The models of
the sub-samples by type of AMI included only factors
which significantly (p < 0.05) contributed to the model
using forward selection technique.
To investigate the associations between in-hospital
treatment strategy and 28-day-case fatality, further mul-
tivariable logistic regression models for each AC were
performed. In addition to the above mentioned variables,
the following potential confounding factors were consid-
ered: in-hospital cardiac arrest (yes/no), any other in-
hospital complication (cardiogenic shock or ventricular
fibrillation or ventricular tachycardia or recurrent infarc-
tion or pulmonary edema or bradycardia [heart rate
<50/min] or stroke or any major bleeding complication
[intracranial or retroperitoneal or any other major spon-
taneous bleeding]) (yes/no), married (yes/no/missing),
and use of the following evidence-based medication
regarded as cornerstone of long-term medical therapy in
ACS patients [1–5]: dual antiplatelet therapy, beta-
blockers, angiotensin-converting-enzyme inhibitors or
angiotensin receptor blockers (ACEIs/ARBs), and statins.
We considered a model for each AC adjusted for sex
and a full model with additional adjustment for all
bivariately significant (p < 0.05) variables. A forward
stepwise selection technique was used. Variables with
more than 2 characteristic (e.g., yes/no/missing) were
‘dummy’-coded.
All analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, North Carolina).
Results
The study population consisted of 3475 patients (69.0 %
men) with a median age of 69.0 years (interquartile
range 58–76 years). There were 1329 (38.2 %) patients
in AC 1, 1083 (31.2 %) in AC 2, and 1063 (30.6 %) in
AC 3. Baseline characteristics, in-hospital procedures
and in-hospital medications according to ACs are shown
in Tables 1 and 2. The 3 ACs significantly differed from
each other in terms of the analyzed variables except for
pre-hospital time and the use of at least 1 antiplatelet
agent. The proportion of patients not receiving an inva-
sive therapy was 10.7, 17.7, and 35.8 % in AC 1, 2, and 3;
in the sub-group of STEMI patients it was 3.4, 7.6, and
16.4 %, respectively. In general, patients with NSTEMI
or BBB were less likely to receive coronary angiography,
invasive therapy and the evidence-based medication (ex-
cept for beta-blockers) compared with STEMI patients
(Table 2). The highest proportion of patients treated
conservatively was observed in AC 3 in patients with
BBB (47.6 %) and with NSTEMI (41.9 %); both sub-
groups showed the lowest rate of angiography of 71.7
and 74.0 %, respectively (Table 2).
Factors associated with in-hospital treatment strategy
The multivariable logistic regression models revealed
that type of AMI (NSTEMI vs. STEMI and BBB vs.
STEMI), LVEF (LVEF ≤30 vs. LVEF >30 % and LVEF not
assessed or missing vs. LVEF >30 %), prior stroke, no
hyperlipidemia, and low peak CPK level were strong pre-
dictors of non-invasive therapy in all ACs (Table 3). Be-
ing a woman was a significant predictor in AC 2 (odds
ratio [OR] 1.80; 95 % confidence interval [CI] 1.24–2.61)
and AC 3 (OR 1.38; 95 % CI 1.03–1.85); whereas renal
dysfunction and prior MI was significantly associated
with non-invasive therapy in AC 1 and 2. Stratifying the
models by type of AMI showed more differentiated re-
sults. For example, in patients with STEMI 3 factors
were associated with non-invasive therapy: prior stroke
in AC 1 (OR 11.2; 95 % CI 2.58–48.7), female sex in AC
2 (OR 2.35; 95 % CI 1.06–5.21), and LVEF (reduced
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LVEF and/or LVEF not assessed/missing) in all ACs. In
patients with NSTEMI, LVEF was seen as predictor in
all ACs, whereas patients with renal dysfunction, prior
MI and history of chronic obstructive pulmonary disease
demonstrated higher odds of receiving conservative ther-
apy in AC 1 and 2. Prior stroke was observed as strong
predictor in AC 3 with NSTEMI (Table 3).
Association between invasive therapy and 28-day-case
fatality
In addition to baseline characteristics previously re-
ported, Table 4 shows that the 3 ACs significantly dif-
fered from each other in terms of the analyzed outcome
and several complications during hospitalization except
for ventricular fibrillation, bradycardia, stroke, and any
Table 1 Baseline characteristics of the study population by age category (n = 3475)
Age category
Variable 25–64 years n = 1329 (38.2) 65–74 years n = 1083 (31.2) 75–84 years n = 1063 (30.6) p Value
Sociodemographics
Age (years)a 55 (49–60) 70 (68–72) 79 (77–81) <0.0001
Female sex 251 (18.9) 327 (30.2) 500 (47.0) <0.0001
Marriedb 885 (69.6) 777 (75.6) 607 (61.9) <0.0001
Living aloneb 255 (20.1) 189 (18.4) 278 (28.4) <0.0001
Body mass index ≥30 kg/m2 413 (31.1) 255 (23.6) 183 (17.2) <0.0001
Smoker <0.0001
Current smoker 714 (53.7) 201 (18.6) 74 (7.0)
Ex-smoker 337 (25.4) 403 (37.2) 308 (29.0)
Never-smoker 234 (17.6) 391 (36.1) 476 (44.8)
missing/not known 44 (3.3) 88 (8.1) 205 (19.3)
Medical historyc
Prior MI 181 (13.6) 228 (21.1) 244 (23.0) <0.0001
Prior stroke 51 (3.8) 117 (10.8) 171 (16.1) <0.0001
Diabetes 353 (26.6) 439 (40.5) 439 (41.3) <0.0001
Hypertension 910 (68.5) 885 (81.7) 943 (88.7) <0.0001
Hyperlipidemia 631 (47.5) 538 (49.7) 453 (42.6) 0.004
Angina pectoris 135 (10.2) 187 (17.3) 210 (19.8) <0.0001
Chronic obstructive pulmonary disease 50 (3.8) 92 (8.5) 92 (8.7) <0.0001
Clinical characteristics
Type of AMI <0.0001
STEMI 625 (47.0) 369 (34.1) 298 (28.0)
NSTEM 651 (49.0) 603 (55.7) 599 (56.4)
Bundle branch block 53 (4.0) 111 (10.2) 166 (15.6)
Peak serum CPK level (U/l)a,b 744 (265–1915) 530 (212–1292) 395 (173–991) <0.0001
LVEF <0.0001
> 30 % 1141 (85.8) 841 (77.7) 711 (67.0)
≤ 30 % 73 (5.5) 87 (8.0) 123 (11.5)
not assessed/missing 115 (8.7) 155 (14.3) 229 (21.5)
Renal dysfunctiond 54 (4.1) 159 (14.7) 306 (28.8) <0.0001
Pre-hospital time/symptom onset to arrival (min)a 159 (79–585) 175 (77–613) 188 (75–565) 0.95
Data are presented as number (percentage) unless otherwise indicated. P values were calculated for comparison of the age categories
AMI acute myocardial infarction, STEMI ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, CPK creatine phosphokinase, LVEF left
ventricular ejection fraction
a Presented as median values (25th, 75th percentiles)
b Values were calculated without patients with missing data regarding married (n = 195), living alone status (n = 195), and peak serum CPK level (n = 23)
c Patient-reported medical history of known comorbidities before the acute event, which was collected with a standardized interview during hospital stay and
further data were gathered in a concluding chart review. If the information on comorbidities from patient-report and medical chart differed, the chart information
was used
d Information on renal dysfunction was collected by review of medical chart
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major bleeding complication. The highest 28-day-case
fatality of 19.5 % (n = 74) was observed in AC 3 receiving
conservative therapy and the lowest (2.4 %; n = 28) in pa-
tients aged 28–65 years treated invasively. In general,
28-day-case fatality was lower in the invasively than
non-invasively treated patients in all ACs.
In the multivariable logistic regression analyses, inva-
sive therapy showed a strongly inverse relation with 28-
day-case fatality compared with the conservative therapy
in all ACs. After adjustment for potential confounding
variables the full model (model 2) revealed an OR of
0.35 (95 % CI 0.15–0.84), 0.45 (95 % CI 0.22–0.92), and
0.39 (95 % CI 0.24–0.63) in the AC 1, 2 and 3, respect-
ively (Table 5).
Discussion
In the present registry-based study including 3475 con-
secutively enrolled patients with AMI occurring between
2009 and 2012, we found that several factors such as
type of AMI, reduced LVEF, prior stroke, history of no
hyperlipidemia, and a low CPK level were strong predic-
tors of a non-invasive therapy independent of age. The
sub-group analysis by type of AMI revealed more inde-
pendent predictors in patients with NSTEMI compared
to STEMI. In addition, besides various differences ob-
served between the 3 age groups, we found that an inva-
sive therapy was inversely associated with 28-day-case
fatality with almost similar mortality risk reductions in
all age groups.
Our findings that NSTEMI and prior stroke were
strong predictive factors are in concordance with an
earlier study conducted in 1001 elderly STEMI and
NSTEMI patients in Germany, which additionally found
age, prior MI, renal failure, pre-existing coronary artery
disease, Killip Class >II, and supraventricular tachycardia
as factors predicting treatment type in patients above
75 years [17]. Our analysis by age groups and type of
AMI adds that renal dysfunction and prior MI were sig-
nificantly associated only in patients presenting with
NSTEMI below 75 years. In contrast to our study, where
female sex was associated with non-invasive therapy in
the total sample above 64 years, Rittger et al. [17] re-
ported that sex had no significant influence on treatment
strategy in patients above 75 years. After stratifying the
study population by type of AMI, we found that women
demonstrated 2-fold higher odds of receiving conserva-
tive therapy only in patients aged 65–74 years diagnosed
with either STEMI or NSTEMI. Even if other factors
such as frailty or severe multimorbidity could have
biased sex differences found in observational studies, es-
pecially in STEMI patients (see below), one should con-
sider the recently updated clinical practice guideline of
the American College of Cardiology and the American
Heart Association which highlights that both genders
Table 2 In-hospital procedures and treatment strategy by age category and stratified by type of AMI (n = 3475)
Age category
Variable 25–64 years n = 1329 (38.2) 65–74 years n = 1083 (31.2) 75–84 years n = 1063 (30.6) p Value





























Coronary angiography 622 (99.5) 606 (93.1) 48 (90.6) 361 (97.8) 534 (88.6) 94 (84.7) 272 (91.3) 443 (74.0) 119 (71.7) 0.003
Treatment strategy <0.0001
PCI 554 (88.6) 460 (70.7) 31 (58.4) 295 (79.9) 346 (57.4) 69 (62.2) 215 (72.2) 272 (45.4) 72 (43.4)
CABG 49 (7.8) 84 (12.9) 9 (17.0) 46 (12.5) 118 (19.6) 17 (15.3) 33 (11.1) 76 (12.7) 15 (9.0)
No invasive therapya 21 (3.4) 106 (16.3) 13 (24.5) 28 (7.6) 138 (22.9) 24 (21.6) 49 (16.4) 251 (41.9) 79 (47.6)
Thrombolysis 1 (0.2) 1 (0.2) 0 0 1 (0.2) 1 (0.9) 1 (0.3) 0 0
Evidence-based medication
Antiplatelet agents 623 (99.7) 643 (98.8) 52 (98.1) 367 (99.5) 600 (99.5) 109 (98.2) 295 (99.0) 590 (98.5) 164 (98.8) 0.24
DAPT 587 (93.9) 543 (83.4) 44 (83.0) 329 (89.2) 459 (76.1) 82 (73.9) 253 (84.9) 404 (67.5) 117 (70.5) <0.0001
Beta-blockers 601 (96.2) 635 (97.5) 50 (94.3) 351 (95.1) 581 (96.4) 105 (94.6) 274 (92.0) 565 (94.3) 155 (93.4) 0.0006
Statins 596 (95.4) 612 (94.0) 48 (90.6) 346 (93.8) 562 (93.2) 94 (84.7) 270 (90.6) 521 (87.0) 147 (88.6) <0.0001
ACEIs/ARBs 587 (93.9) 584 (89.7) 48 (90.6) 337 (91.3) 544 (90.2) 96 (86.5) 255 (85.6) 507 (84.6) 139 (83.7) <0.0001
Data are presented as number (percentage). P values were calculated for comparison of the age categories. Data of the total sample of each age category are not
presented in this table, but used for comparison tests
AMI acute myocardial infarction, STEMI ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, BBB bundle branch block, PCI
percutaneous coronary intervention, CABG coronary artery bypass graft, DAPT dual antiplatelet therapy, ACEIs/ARBs angiotensin-converting enzyme inhibitors or
angiotensin-receptor blockers
a Invasive therapy was defined as PCI with stent implantation or balloon dilatation or/and CABG
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Table 3 Factors associated with non-invasive therapy by age category for the total sample and stratified by type of AMI
Age category
25–64 years 65–74 years 75–84 years
OR [95 % CI] p Value OR [95 % CI] p Value OR [95 % CI] p Value
Total sample (n = 3452)a (n = 1324) (n = 1077) (n = 1051)
Sex (women vs. men) 1.28 [0.80–2.06] 0.30 1.80 [1.24–2.61] 0.002 1.38 [1.03–1.85] 0.03
Type of AMI (NSTEMI vs. STEMI) 3.07 [1.81–5.20] <0.0001 2.54 [1.59–4.05] <0.0001 2.36 [1.59–3.51] <0.0001
Type of AMI (BBB vs. STEMI) 4.22 [1.76–10.1] 0.001 2.01 [1.05–3.84] 0.03 2.60 [1.58–4.26] 0.001
Prior stroke (yes vs. no) 2.97 [1.40–6.30] 0.005 1.91 [1.17–3.13] 0.01 1.87 [1.27–2.75] 0.002
Renal dysfunction (yes vs. no) 2.27 [1.06–4.90] 0.04 1.59 [1.03–2.45] 0.04 1.35 [0.97–1.87] 0.07
Prior MI (yes vs. no) 2.08 [1.27–3.41] 0.004 2.00 [1.35–2.95] 0.001 1.27 [0.89–1.81] 0.18
LVEF (LVEF≤ 30 % vs. LVEF > 30 %) 3.28 [1.60–6.71] 0.001 1.85 [1.02–3.35] 0.04 2.02 [1.30–3.14] 0.002
LVEF (LVEF n/mb vs. LVEF > 30 %) 6.58 [4.05–10.7] <0.0001 5.03 [3.32–7.63] <0.0001 6.10 [4.27–8.73] <0.0001
History of hyperlipidemia (yes vs. no) 0.52 [0.34–0.80] 0.003 0.63 [0.44–0.90] 0.01 0.67 [0.49–0.91] 0.01
History of COPD (yes vs. no) 1.89 [0.87–4.13] 0.11 2.26 [1.34–3.81] 0.002 0.83 [0.50–1.39] 0.48
Peak serum CPK level (U/l) (continuous) 1.00 [1.00–1.00] 0.003 1.00 [1.00–1.00] 0.04 1.00 [1.00–1.00] <0.0001
STEMI (n = 1292) (n = 625) (n = 369) (n = 298)
Sex (women vs. men) n/ac 2.35 [1.06–5.21] 0.04 n/ac
Prior stroke (yes vs. no) 11.2 [2.58–48.7] 0.001 n/ac n/ac
LVEF (LVEF≤ 30 % vs. LVEF > 30 %) 3.71 [1.01–13.6] 0.05 2.36 [0.74–7.54] 0.15 1.53 [0.58–4.03] 0.39
LVEF (LVEF n/mb vs. LVEF > 30 %) 4.13 [1.22–14.0] 0.02 3.90 [1.30–11.7] 0.02 13.0 [5.72–29.3] <0.0001
NSTEMI (n = 1838) (n = 647) (n = 603) (n = 588)
Sex (women vs. men) n/ac 1.63 [1.04–2.53] 0.03 n/ac
Prior stroke (yes vs. no) n/ac n/ac 2.15 [1.34–3.46] 0.002
Renal dysfunction (yes vs. no) 2.76 [1.18–6.45] 0.02 1.80 [1.09–2.99] 0.02 n/ac
Prior MI (yes vs. no) 1.81 [1.03–3.18] 0.04 2.04 [1.30–3.21] 0.002 n/ac
LVEF (LVEF≤ 30 % vs. LVEF > 30 %) 3.08 [1.15–8.22] 0.03 1.88 [0.86–4.13] 0.12 3.19 [1.75–5.80] 0.001
LVEF (LVEF n/mb vs. LVEF > 30 %) 6.24 [3.56–10.9] <0.0001 5.04 [3.12–8.16] <0.0001 5.49 [3.54–8.50] <0.0001
History of hyperlipidemia (yes vs. no) 0.52 [0.32–0.85] 0.01 n/ac 0.51 [0.35–0.74] 0.001
History of COPD (yes vs. no) 2.57 [1.05–6.32] 0.04 2.11 [1.16–3.85] 0.01 n/ac
Peak serum CPK level (U/l) (continuous) 1.00 [1.00–1.00] 0.001 n/ac 1.00 [1.00–1.00] 0.005
BBB (n = 330) (n = 53) (n = 111) (n = 165)
Prior MI (yes vs. no) 9.18 [1.62–51.9] 0.01d 3.17 [1.10–9.12] 0.03 n/ac
Renal dysfunction (yes vs. no) 18.8 [1.04–340.0] 0.05d n/ac n/ac
History of hypertension (yes vs. no) 0.11 [0.02–0.68] 0.02d n/ac n/ac
LVEF (LVEF≤ 30 % vs. LVEF > 30 %) N/Ae 2.41 [0.65–8.99] 0.19 1.14 [0.46–2.83] 0.79
LVEF (LVEF n/mb vs. LVEF > 30 %) N/Ae 10.5 [3.27–33.7] <0.0001 9.44 [3.89–22.9] <0.0001
Peak serum CPK level (U/l) (continuous n/ac n/ac 1.00 [1.00–1.00] 0.01
The multivariable analysis included as explanatory variables sex, type of AMI (‘dummy’-coded), LVEF (‘dummy’-coded), renal dysfunction, prior stroke, prior MI,
history of diabetes, hypertension, hyperlipidemia, angina pectoris and COPD, pre-hospital time, and peak serum CPK level. In the total sample, variables which
meet the 0.05 significance level in at least one age category were included and presented. For the sub-samples by type of AMI only the significant factors in that
sub-sample model (forward stepwise selection technique) were included and presented
OR odds ratio, CI confidence interval, AMI acute myocardial infarction, STEMI ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, BBB
bundle branch block, LVEF left ventricular ejection fraction, COPD chronic obstructive pulmonary disease, CPK creatine phosphokinase
a As 23 patients had no data on peak serum CPK level, the total sample size was 3452 instead of 3475
b n/m, LVEF were not assessed or missing
c n/a, OR and p value were not applicable because the analyzed variable did not meet the 0.05 significance level for entry into the model of the sub-sample
d P value and OR were assessed in a separate model without the variables regarding LVEF
e N/A, not applicable due to quasi-complete separation of data points detected when ‘LVEF’ was included
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should be treated in the same way [18]. It is known from
earlier studies that prevalence of frailty and multiple co-
morbidities influence the likeliness of receiving invasive
therapy and also the outcome of elderly ACS patients
[5, 19–21], and were found to be more common in
women [21–24]. Therefore, for clinical decision-making
and evaluation of the prognosis of elderly ACS patients
an assessment tool for end-of-life status, which showed
comparable usefulness with clinical risk scores such as
the Global Registry of Acute Coronary Events (GRACE)
score, might be considered to predict the 1-year all-
cause mortality and to select the approximately 8 % of
patients with an end-stage illness [22].
In the sub-group of STEMI patients we observed that
only a small number did not receive invasive therapy,
but this proportion increased by age from 3.4 % in AC 1
to 16.4 % in AC 3. Our multivariable analyses revealed
only 3 predictive factors for non-invasive therapy in
STEMI patients: LVEF in all ACs, prior stroke in pa-
tients below 65 years and female sex in patients aged
65–74 years. ORs of 11 (prior stroke) and 4–13 (LVEF)
indicate a strong impact of these factors in STEMI pa-
tients. Prior stroke was also reported as predictor of
non-invasive therapy in earlier studies regarding STEMI
patients [11, 13]. Our study adds that reduced LVEF or
heart failure and cardiac enzyme levels such as CPK or
troponin might be more important than other factors
previously reported. Regarding female sex, a discrepancy
between previous reported results exists. Gharacholou
et al. [11] reported that female sex was identified as
strong factor associated with no reperfusion among the
reperfusion-eligible STEMI population analyzed from
Table 4 Clinical complications and outcome by age category and stratified by treatment strategy (n = 3475)
Age category





























Complications during hospital stay
Cardiac arrest 76 (5.7) 58 (4.9) 18 (12.7) 110 (10.2) 79 (8.9) 31 (16.2) 176 (16.6) 102 (14.9) 74 (19.5) <0.0001
Cardiogenic shock 54 (4.1) 48 (4.0) 6 (4.2) 77 (7.1) 66 (7.4) 11 (5.7) 101 (9.5) 75 (11.0) 26 (6.8) <0.0001
Ventricular fibrillation 32 (2.4) 29 (2.4) 3 (2.1) 32 (3.0) 27 (3.0) 5 (2.6) 31 (2.9) 25 (3.7) 6 (1.6) 0.65
Ventricular tachycardia 109 (8.2) 105 (8.9) 4 (2.8) 66 (6.1) 60 (6.7) 6 (3.1) 54 (5.1) 41 (6.0) 13 (3.4) 0.007
Bradycardia 76 (5.7) 72 (6.1) 4 (2.8) 71 (6.6) 67 (7.5) 4 (2.1) 63 (5.9) 51 (7.5) 12 (3.2) 0.68
Re-infarction 10 (0.8) 10 (0.8) 0 18 (1.7) 13 (1.5) 5 (2.6) 26 (2.5) 20 (2.9) 6 (1.6) 0.04
Stroke 5 (0.4) 5 (0.4) 0 9 (0.8) 7 (0.8) 2 (1.0) 8 (0.8) 5 (0.7) 3 (0.8) 0.32
Pulmonary edema 30 (2.3) 25 (2.1) 5 (3.5) 43 (4.0) 33 (3.7) 10 (5.2) 57 (5.4) 41 (6.0) 16 (4.2) 0.0003
Any major bleeding complicationa 13 (1.0) 11 (0.9) 2 (1.4) 19 (1.8) 14 (1.6) 5 (2.6) 22 (2.1) 16 (2.3) 6 (1.6) 0.08
Any in-hospital complication
(without cardiac arrest)
254 (19.1) 236 (19.9) 18 (12.7) 243 (22.4) 208 (23.3) 35 (18.2) 249 (23.4) 185 (27.1) 64 (16.8) 0.02
Outcome
28-day-case fatality 44 (3.3) 28 (2.4) 16 (11.3) 74 (6.8) 44 (4.9) 30 (15.6) 138 (13.0) 64 (9.4) 74 (19.5) <0.0001
Death during hospital stay 43 (3.2) 28 (2.4) 15 (10.6) 74 (6.9) 45 (5.1) 30 (15.6) 146 (13.7) 72 (10.5) 74 (19.5) <0.0001
Data are presented as number (percentage). P values were calculated for comparison of the age categories
IT invasive therapy, CT conservative therapy
a Major bleeding complication: intracranial or retroperitoneal or any other major spontaneous bleeding
Table 5 Association between invasive therapy and 28-day-case fatality by age category
Age category
25–64 years 65–74 years 75–84 years
OR [95 % CI] p Value OR [95 % CI] p Value OR [95 % CI] p Value
Model 1a 0.19 [0.10–0.36] <0.0001 0.28 [0.17–0.46] <0.0001 0.43 [0.30–0.62] <0.0001
Model 2b 0.35 [0.15–0.84] 0.02 0.45 [0.22–0.92] 0.03 0.39 [0.24–0.63] <0.0001
a Model 1 adjusted for sex for the total sample (n = 3475)
b Model 2 adjusted for sex, body mass index ≥30 kg/m2, type of AMI, renal dysfunction, prior stroke, prior MI, history of diabetes, hypertension, hyperlipidemia,
angina pectoris and chronic obstructive pulmonary disease, any in-hospital complication (without cardiac arrest), pre-hospital time, left ventricular ejection fraction,
peak serum creatine phosphokinase (CPK) level, and in-hospital medication: dual antiplatelet therapy, beta-blockers, statins, and angiotensin-converting-enzyme
inhibitors or angiotensin receptor blockers. As 23 patients had no data on peak serum CPK level, the total sample size was 3452
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226 US hospitals participating in the CRUSADE quality
improvement initiative. Another study also reported an
association between female sex and not attempting re-
perfusion in STEMI patients [7]. In contrast, some earl-
ier studies [23, 24] found that being a woman was not
an independent predictor in patients presenting with
STEMI. As we analyzed factors by age, our study adds
the information that female sex might be an independ-
ent predictor in patients who were between 65 and 74
years old. However, as mentioned above, missing adjust-
ment for unobserved confounders related with female
sex such as frailty, multiple comorbidities or high risk of
death could have biased our and previously reported
studies. This theory is supported by a recent study in
1104 STEMI patients based on two clinical network
registries in Germany which reported that standard of
care including performance of primary PCI and proced-
ural success rate were not gender specific, and the ad-
justed 12-months mortality did not differ between men
and women despite significant differences in clinical
baseline parameters [25]. However, gender differences
in clinical decision-making regarding reperfusion rates
and secondary drug treatment prophylaxis were still re-
ported in several countries [26–29]. In contrast to earl-
ier studies in STEMI patients, we did not find diabetes
[7, 9, 12], prior MI [9] and delayed presentation (pre-
hospital time) [13, 23, 24] as being predictive factors in
this sub-group. The comparison across studies is, how-
ever, difficult, since we were not able to adjust our ana-
lyses for other potential reasons such as patient
preference, dementia [13], or contraindications to the
use of reperfusion, prior CABG, spontaneous reperfu-
sion [10] or Killip class risk score [10, 17]. In general,
we observed that previous reported results vary consid-
erably depending mainly on study design, time period,
analyzed factors, proportion of patients not receiving in-
vasive therapy, and country of origin.
Regarding 28-day-case fatality, we observed a clear
short-term survival benefit associated with invasive ther-
apy in all 3 age groups after adjustment for various con-
founding factors including type of AMI, evidence-based
medication and in-hospital complications. In contrast to
earlier trials [1, 5, 30], we did not observe greater risk re-
duction from the invasive therapy in patients above
64 years. The ORs found in our study were almost simi-
lar, but showed a narrower CI in the eldest group, which
strengthens the benefit of an invasive therapy for
reperfusion-eligible patients above 74 years. In addition,
the occurrence of major bleeding complications was not
significantly different between the ACs in our study, but
showed a higher rate in the invasively treated patients
only in the oldest age group. However, as we did not
know the time point of complications’ appearance dur-
ing hospitalization, we cannot exclude that bleeding
complications might have been present before invasive
therapy. In summary, our results regarding short-term
survival confirmed the previously reported benefit of in-
vasive therapy in AMI patients up to 84 years [5, 31–
35]. However, we cannot exclude that the benefit of in-
vasive therapy coexists with a higher risk of major bleed-
ing in patients above 74 years of age as reported
previously [1, 5].
Strength and limitations
Major strength of our study is the setting in a
population-based registry with patients consecutively
hospitalized with all types of AMI and data collection
performed soon after the AMI during the hospital stay.
Furthermore, our research covers recent data up to
2012. Despite adjustment for a number of variables, re-
sidual confounding cannot be entirely excluded due to
further unknown comorbidities or complications such as
frailty, cancer and cognitive and physical function, which
could have influenced decision to perform an invasive
therapy and also short-term mortality. As we do not
have information on Killip class, GRACE risk score and
comorbid anemia for patients included in this study, we
were not able to analyze these potential predictors of
clinical decision-making in today’s real-life patient care.
In addition, we were not able to address the issue of
contraindications or eligibility to the use of invasive pro-
cedures, and documented reasons for non-invasive ther-
apy were not assessed in our registry. Finally, our results
are limited to AMI- patients who survived at least 24 h
after hospitalization and were between 26 and 84 years
old.
Conclusion
In today’s real-life patient care we found that NSTEMI,
BBB, prior stroke, reduced LVEF, absence of hyperlipid-
emia, and low CPK level were the strongest predictors
for non-invasive therapy in all age groups. Stratifying the
analysis by type of AMI revealed more independent pre-
dictors in patients with NSTEMI compared to STEMI.
Further research is necessary to investigate the real rea-
sons for non-invasive therapy, especially among elderly
women. Moreover, we confirmed that invasive therapy
was independently associated with short-term survival
benefit regardless of patient’s age.
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